229 related articles for article (PubMed ID: 27478469)
1. Botulinum toxin A in the treatment of Raynaud's phenomenon: a systematic review.
Żebryk P; Puszczewicz MJ
Arch Med Sci; 2016 Aug; 12(4):864-70. PubMed ID: 27478469
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin A treatment of Raynaud's phenomenon: a review.
Iorio ML; Masden DL; Higgins JP
Semin Arthritis Rheum; 2012 Feb; 41(4):599-603. PubMed ID: 21868066
[TBL] [Abstract][Full Text] [Related]
3. Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience.
Nagarajan M; McArthur P
Rheumatol Int; 2021 May; 41(5):943-949. PubMed ID: 32447423
[TBL] [Abstract][Full Text] [Related]
4. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Botulinum Toxin Type A and its Potential Effect on Exacerbated Raynaud's Phenomenon in Hospitalized Scleroderma Patients.
Seyedmardani SM; Aghdashi MA; Soltani S; Zonouz GK
Curr Rheumatol Rev; 2022; 18(1):48-57. PubMed ID: 34636314
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type A in the treatment of Raynaud's phenomenon.
Habib SM; Brenninkmeijer EEA; Vermeer MH; de Vries-Bouwstra JK; Velthuis PJ
Dermatol Ther; 2020 Nov; 33(6):e14182. PubMed ID: 32794364
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis.
Jokar MH; Baghbani B; Geraylow KR; Shariati J; Mehrad-Majd H; Mirfeizi Z; Hashemzadeh K
Reumatologia; 2022; 60(6):392-398. PubMed ID: 36683833
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin in the management of primary and secondary Raynaud's phenomenon.
Ennis D; Ahmad Z; Anderson MA; Johnson SR
Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101684. PubMed ID: 33965340
[TBL] [Abstract][Full Text] [Related]
9. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.
Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
Cochrane Database Syst Rev; 2000; 1998(2):CD000953. PubMed ID: 10796395
[TBL] [Abstract][Full Text] [Related]
10. Clinical and image improvement of Raynaud's phenomenon after botulinum toxin type A treatment.
Zhao H; Lian Y
Australas J Dermatol; 2015 Aug; 56(3):202-5. PubMed ID: 25817568
[TBL] [Abstract][Full Text] [Related]
11. The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes.
Dhaliwal K; Griffin M; Denton CP; Butler PEM
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29525756
[TBL] [Abstract][Full Text] [Related]
12. Ischemic ulcers of the toes secondary to Raynaud's phenomenon in a child successfully treated with botulinum toxin.
Quintana Castanedo L; Feito Rodríguez M; Maseda Pedrero R; Chiloeches Fernández C; de Lucas Laguna R
Pediatr Dermatol; 2020 Jul; 37(4):681-683. PubMed ID: 32212180
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
Motegi SI; Uehara A; Yamada K; Sekiguchi A; Fujiwara C; Toki S; Date Y; Nakamura T; Ishikawa O
Acta Derm Venereol; 2017 Jul; 97(7):843-850. PubMed ID: 28358168
[TBL] [Abstract][Full Text] [Related]
14. The Use of Botulinum Toxin in Raynaud Phenomenon: A Comprehensive Literature Review.
Lawson O; Sisti A; Konofaos P
Ann Plast Surg; 2023 Jul; 91(1):159-186. PubMed ID: 37450876
[TBL] [Abstract][Full Text] [Related]
15. Is axillary botulinum toxin efficient in controlling secondary Raynaud's phenomenon? A case report.
DeMasters D; Sturgill E; Bartholomew A
J Scleroderma Relat Disord; 2021 Oct; 6(3):327-329. PubMed ID: 35387220
[TBL] [Abstract][Full Text] [Related]
16. Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series.
Dhaliwal K; Griffin MF; Salinas S; Howell K; Denton CP; Butler PEM
Clin Rheumatol; 2019 Dec; 38(12):3669-3676. PubMed ID: 31482318
[TBL] [Abstract][Full Text] [Related]
17. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
Colakoğlu M; Cobankara V; Akpolat T
Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type A in the treatment of Raynaud's phenomenon.
Neumeister MW
J Hand Surg Am; 2010 Dec; 35(12):2085-92. PubMed ID: 21134617
[TBL] [Abstract][Full Text] [Related]
19. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma.
Uppal L; Dhaliwal K; Butler PE
J Hand Surg Eur Vol; 2014 Oct; 39(8):876-80. PubMed ID: 24369360
[TBL] [Abstract][Full Text] [Related]
20. Raynaud's phenomenon (secondary).
Herrick A; Muir L
BMJ Clin Evid; 2014 Oct; 2014():. PubMed ID: 25322727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]